U.S. Markets closed

Omeros Corporation (OMER)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
21.96+0.12 (+0.55%)
At close: 4:00PM EDT
People also watch
TGTXPTLAFOLDSGYPOCUL
  • It is more likely that IgA will get approve by end of year and aHUS late 2018. This will be do to a couple of things. One, no approved drug for IgA
    A much larger group of people with IgA, and after such great data from the phase II trial , it is very likely to get accelerated approval before the phase III trial even ends. (Very similar to the Soliris trials) IMO we will be marketing OMS721 and the sales will exceed 5 Billion within 2years. If you read the Cowen report there are apps. 180,000 people yearly that are diagnosed with IgA , Cowen believes that the price would be in the $100,000 range per treatment. If only half of the patients get to use it.90,000 X $100,000 you got $9 Billion and this is only in the USA. EUORPE AND ASIA much larger numbers. aHUS is a much small group, much harder to enroll, and very tricky to deal with.
  • After OMS721 goes to market, there should essentially be a 10x multiplier on our current PPS, if not more
  • Don't bet against Dr. D...
  • Barron's Winners and Losers this weekend, ACRX # 3 up 31%. Don't bet against Omeros co-founder (in fact, don't bet against anything to do with Omeros), Dr. Pamela Palmer: ACRX Co-Founder, Chief Medical Officer and Director

    Pamela P. Palmer, M.D., Ph.D. Pamela Palmer is a co-founder of ****Omeros**** and remains actively involved as a consultant in the Company’s ongoing research efforts.
  • What will happen when a 1st tier brokerage initiates coverage on OMER?
    Merrill, Morgan S, GS,
  • I would TOTALLY agree with you! at an average of a 4x multiplier of realistic predicted sales imo the total market cap for OMS721 alone will be over $1 Billion out of $3B that's it's competitor has currently assume NO growth in either of the two sections:

    $1B in Revenue * 4x multiplier = $4 Billion market cap

    Super NO BRAINer!!!! and then add in.:

    OMEDRIA $50M Revenue *3x multiplier= $1.5 Billion in Market Cap

    Added together, IF my math is CORRECT?
  • https://www.bizjournals.com/seattle/news/2017/07/20/omeros-wins-court-order-against-twitter-critic.html

    Omeros wins court order against Twitter critic whose accusations caused stock to drop - Puget Sound Business Journal
    The Seattle-based biotech's lawsuit said anonymous allegations knocked more than $200 million of its market capitalization.
    www.bizjournals.com
  • Options X tomorrow. I think they will work it back down to $21.50-$21.50. We will then wait for earnings report on $1.50 share price movements. Just stay in channel. The earnings week will be the games played but not relevant. We will sit @ or below $30 until cash is better or a partnership.

    With the extensive pipeline costs you will get little to no credit for Omidria growth. It has been on a solid linear pattern and without hitting exit velocity study costs will continue to greatly exceed revs. They are cheeper, short term, than drug commercialization costs. Short term a real catalyst is partnership. Revs may show from it in two quarters if solid uptake.

    OMER will do its DD on their studies, they will be thorough but they may be long.

    Hang in there.

    Long @ $9.12 since 2013

    SS SensiSEATTLE
  • Not sure what the odds are that OMER holds this early gain through EOD
  • Nice volume in the first hour over 200k and up.
  • I see a slow but steady rise to $24-$26 before ECC. Then a large pop to $30 after ECC.
    If European partnership is announced or FDA approval, $40-$60/share
  • Good week for biotech. Should continue for for awhile.
  • Bunch of drowning shorties yelling about dilution. Shorty, please.

    If you're long study the credit facility and wait for earnings
  • Closing remarks on last C, Dr. Greg Demopulos

    Thank you, Operator. And thank you again everyone for taking the time to listen in. Clearly these are exciting times for Omeros. OMIDRIA sales continue to drain traction. Our Phase 3 OMS721 program is underway and as I said, two more are expected to quickly join it. One addiction programs in Phase 2 and the next OMS527 is rapidly advancing to the clinic. We expect that all of these programs and the rest of our pipeline will continue to generate a long line of near-term milestones and we look forward to keeping you updated on those milestones and our achievement of them. As always, we appreciate your continued interest and support. Have a good day. Thank you
  • No one is writing calls. I couldn't buy any $25's 8/17/17

    Gonna go looking for suckers again tomorrow
  • I tell you if you have something intelligent and different you have to share with the group than share away. Please keep the communication in the past of Ra Ra chickabob needs to halt immediately save it to Facebook. Thanks?
  • Make the announcement already. They've had the approval letter for a week now, wonder what their waiting for.
  • Here we go, hold on tight!
  • No need for dilution any time soon - and depending on Omidria sales maybe no need for dilution ever.
  • Nobody taking profits at end of day, a very good sign